Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 169-176

  Koga, Yoshikatsu ^a   Yamazaki, Nobuyoshi ^a   Takizawa, Satoko ^b   Kawauchi, Junpei ^b   Nomura, Osamu ^b   Yamamoto, Seiichiro ^c   Saito, Norio ^a   Kakugawa, Yasuo ^d   Otake, Yosuke ^d   Matsumoto, Minori ^d   Matsumura, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b TORAY INDUSTRIES INC   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

Author keywords

Cancer screening; Colorectal cancer; DNA microarray; Fecal occult blood test; Fecal RNA; Gene profiling

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; FCGR3A PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 8; MANGANESE SUPEROXIDE DISMUTASE; PFKFB3 PROTEIN; PROTEIN; RNA; UNCLASSIFIED DRUG; TUMOR MARKER;

ACCURACY; ADULT; AGED; ARTICLE; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; CANCER STAGING; CASE CONTROL STUDY; CHEMISTRY; COLONOSCOPY; COLORECTAL TUMOR; COMPARATIVE STUDY; EARLY DIAGNOSIS; FECAL OCCULT BLOOD TEST; FECAL RNA; FECES; FOLLOW UP; GENE PROFILING; GENETICS; METABOLISM; MIDDLE AGED; OCCULT BLOOD; PROGNOSIS; SURVIVAL RATE;

CANCER SCREENING; COLORECTAL CANCER; DNA MICROARRAY; FECAL OCCULT BLOOD TEST; FECAL RNA; GENE PROFILING;

ADULT; AGED; CASE-CONTROL STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OCCULT BLOOD; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84897022707     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T and Japan Cancer Surveillance Research G: Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 42: 139-147, 2012.
3. Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T and Research Group of Population-Based Cancer Registries of J: Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol 41: 40-51, 2011.
4. Mandel JS, Church TR, Ederer F and Bond JH: Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91: 434-437, 1999.
5. Jorgensen OD, Kronborg O and Fenger C: A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50: 29-32, 2002.
6. Scholefield JH, Moss S, Sufi F, Mangham CM and Hardcastle JD: Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 50: 840-844, 2002.
7. Lieberman DA, Weiss DG and Veterans Affairs Cooperative Study G: One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 345: 555-560, 2001.
8. Sung JJ, Chan FK, Leung WK, Wu JC, Lau JY, Ching J, To KF, Lee YT, Luk YW, Kung NN, Kwok SP, Li MK and Chung SC: Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology 124: 608-614, 2003.
9. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME and Colorectal Cancer Study G: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351: 2704-2714, 2004.
10. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T and Shiratori Y: A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129: 422-428, 2005.
11. Chen JG, Cai J, Wu HL, Xu H, Zhang YX, Chen C, Wang Q, Xu J and Yuan XL: Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test. World J Gastroenterol 18: 2682-2688, 2012.
12. Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, Vellacott K, Moshakis V and Reynolds JR: Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 46: 795-800, 2000.
13. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M and Bjarnason I: Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49: 402-408, 2001.
14. Yoo BC, Shin YK, Lim SB, Hong SH, Jeong SY and Park JG: Evaluation of calgranulin B in stools from the patients with colorectal cancer. Dis Colon Rectum 51: 1703-1709, 2008.
15. Li R, Liu J, Xue H and Huang G: Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis. Int J Cancer 131: 1837-1845, 2012.
16. Tonus C, Sellinger M, Koss K and Neupert G: Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol 18: 4004-4011, 2012.
17. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ and Hillman SL: Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 149: 441-450, W481, 2008.
18. Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF, Kinzler KW, Vogelstein B, Bjerregaard NC, Laurberg S, Sorensen HT, Berger BM and Lidgard GP: Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142: 248-256; quiz e225-246, 2012.
19. Smith RA, Cokkinides V and Brawley OW: Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin 58: 161-179, 2008.
20. Kanaoka S, Yoshida K, Miura N, Sugimura H and Kajimura M: Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 127: 422-427, 2004.
21. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR and Goel A: Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 19: 1766-1774, 2010.
22. Yamazaki N, Koga Y, Yamamoto S, Kakugawa Y, Otake Y, Hayashi R, Saito N and Matsumura Y: Application of the Fecal MicroRNA Test to the Residuum from the Fecal Occult Blood Test. Jpn J Clin Oncol, 2013.
23. Koga Y, Yamazaki N, Yamamoto Y, Yamamoto S, Saito N, Kakugawa Y, Otake Y, Matsumoto M and Matsumura Y: Fecal miR-106a Is a Useful Marker for Colorectal Cancer Patients with False-Negative Results in Immunochemical Fecal Occult Blood Test. Cancer Epidemiol Biomarkers Prev 22: 1844-1852, 2013.
24. Yajima S, Ishii M, Matsushita H, Aoyagi K, Yoshimatsu K, Kaneko H, Yamamoto N, Teramoto T, Yoshida T, Matsumura Y and Sasaki H: Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer. Int J Oncol 31: 1029-1037, 2007.
25. Nagino K, Nomura O, Takii Y, Myomoto A, Ichikawa M, Nakamura F, Higasa M, Akiyama H, Nobumasa H, Shiojima S and Tsujimoto G: Ultrasensitive DNA chip: gene expression profile analysis without RNA amplification. J Biochem 139: 697-703, 2006.
26. Sato F, Tsuchiya S, Terasawa K and Tsujimoto G: Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS One 4: e5540, 2009.
27. Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M and Haussler D: Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 16: 906-914, 2000.
28. Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS, Ares M, Jr. and Haussler D: Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci USA 97: 262-267, 2000.
29. Chang CC and Lin CJ: LIBSVM: A Library for Support Vector Machines. Acm Transactions on Intelligent Systems and Technology 2: 1-27, 2011.
30. Shah HA, Paszat LF, Saskin R, Stukel TA and Rabeneck L: Factors associated with incomplete colonoscopy: a population-based study. Gastroenterology 132: 2297-2303, 2007.
31. Bressler B, Paszat LF, Vinden C, Li C, He J and Rabeneck L: Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology 127: 452-456, 2004.
32. Weiss JM, Pfau PR, O'Connor ES, King J, LoConte N, Kennedy G and Smith MA: Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results - Medicare data. J Clin Oncol 29: 4401-4409, 2011.
33. Hansen IO and Jess P: Possible better long-term survival in left versus right-sided colon cancer - a systematic review. Dan Med J 59: A4444, 2012.
34. Koppelstaetter C, Jennings P, Hochegger K, Perco P, Ischia R, Karkoszka H and Mayer G: Effect of tissue fixatives on telomere length determination by quantitative PCR. Mech Ageing Dev 126: 1331-1333, 2005.
35. Chowdary D, Lathrop J, Skelton J, Curtin K, Briggs T, Zhang Y, Yu J, Wang Y and Mazumder A: Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative. J Mol Diagn 8: 31-39, 2006.
36. Smink JJ and Leutz A: Instruction of mesenchymal cell fate by the transcription factor C/EBPbeta. Gene 497: 10-17, 2012.
37. Birkenkamp-Demtroder K, Mansilla F, Sorensen FB, Kruhoffer M, Cabezon T, Christensen LL, Aaltonen LA, Verspaget HW and Orntoft TF: Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro. Mol Oncol 1: 181-195, 2007.
38. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S and Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25: 3712-3718, 2007.
39. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R and Bucala R: High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62: 5881-5887, 2002.
40. Ning Y and Lenz HJ: Targeting IL-8 in colorectal cancer. Expert Opin Ther Targets 16: 491-497, 2012.
41. Asfaha S, Dubeykovskiy AN, Tomita H, Yang X, Stokes S, Shibata W, Friedman RA, Ariyama H, Dubeykovskaya ZA, Muthupalani S, Ericksen R, Frucht H, Fox JG and Wang TC: Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology 144: 155-166, 2013.
42. Skrzycki M, Majewska M, Podsiad M and Czeczot H: Expression and activity of superoxide dismutase isoenzymes in colorectal cancer. Acta Biochim Pol 56: 663-670, 2009.
43. Jiang Z, Wang Z, Xu Y, Wang B, Huang W and Cai S: Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer. Biosci Rep 30: 383-390, 2010.